Monthly Archives: December 2024

NIH Common Data Element (CDE) Repository

Posted on by

The practice of re-using a research survey or measurement instrument (while respecting copyright and giving proper attribution) – especially a validated one – is a common one that everyone  (especially research funders) can agree makes research more efficient and cost-effective.  For example, anyone familiar with the REDCap electronic data capture tool is likely aware of the REDCap Shared Library that “is a repository for REDCap data collection instruments and forms that can be downloaded and used by researchers at REDCap partner institutions“. Even NIH survey materials like the NIH’s All of US Programs are available for download from there.



Even though a data collection instrument in its entirety often cannot satisfy the unique needs of an original research project, it is still useful to collect the commonly-used individual data elements/variables of an instrument in a consistent and standardized way (that other researchers are also adopting in their own projects) because this makes the data collected for diverse studies more interoperable (i.e. increases the potential for this information to be shared/combined in future research projects).

And “the use of particular standards to enable interoperability of datasets” is an important component of the 2023 NIH Data Management and Sharing Policy, which aligns with the FAIR data principles – see: 

“NIH has issued the Data Management and Sharing (DMS) policy (effective January 25, 2023) to promote the sharing of scientific data. Sharing scientific data accelerates biomedical research discovery, in part, by enabling validation of research results, providing accessibility to high-value datasets, and promoting data reuse for future research studies.“

This brings us to the NIH Common Data Element (CDE) Repository, which is “hosted and maintained by the National Library of Medicine (NLM)”. To encourage the use of Common Data Elements (CDEs) and make it easier for researchers to identify CDEs that might be useful for their research project, NLM has created this searchable repository/catalog that users can freely access online.

Users can search for individual CDEs or multiple CDEs that are curated into Forms. The search can also be limited to NIH-Endorsed CDEs, which are CDEs that have “been reviewed and approved by an expert panel, and meet established criteria”. Furthermore, “NIH-recognized bodies (institutes, research initiatives, etc.) may submit CDEs to the NIH CDE Governance Committee for consideration for endorsement” via the Repository’s homepage – see: 

NIH Common Data Element (CDE) Repository – https://cde.nlm.nih.gov/home

From the NIH CDE Repository User Guide: https://cde.nlm.nih.gov/guides

“The NIH CDE Repository uses the Unified Medical Language System (UMLS) Terminology Service (UTS) Sign on Service which lets you set up an account and sign in using your NIH credentials, your account with a research organization, or a personal account such as Google, Microsoft, or Login.gov.

A user account is not required to browse the NIH CDE Repository, but when you are signed in, you will have expanded access to features. User account holders can create Boards and save CDEs and Forms to them, remember your preferences on all your devices, and if approved, become a curator, and view/manage your organization’s content. Users with NIH credentials can choose to see CDEs of any registration status – including previewing draft CDEs that have not yet been published.”

NLM also offers these CDE training options where you can learn more:

Questions? Ask Us at the MSK Library!

The New Role of RAS Genes in Cancer, Quitting Smoking Boosts Survival in Cancer Patients, and More

Posted on by
  • In collaboration with other researchers, researchers at the National Institutes of Health discovered an entirely new ways RAS genes, which are “the second most frequently mutated genes in cancer”, drive cancer growth. The knowledge of RAS genes’ role in cancer was well established, but discovering how RAS genes trigger a chain “of events involving the transport of specific proteins in the nucleus” is an entirely new turn. The discovery can pave the way for new drug combinations to treat RAS-promoted cancers more effectively. The study was published in Nature Cancer.
  • Researchers from Washington University in St. Louis (WashU) conducted the phase I clinical trial of an investigational vaccine for the prevention of triple-negative breast cancer recurrence. This small clinical trial of a new type of vaccine, known as a neoantigen DNA vaccine, demonstrated promising, better-than-expected, results for patients with this aggressive, hard-to-treat, type of breast cancer. The study was published in Genome Medicine.
  • Another research that has implications for triple-negative breast cancer, among other cancer types, is conducted at Johns Hopkins University. This research is related to cancer cells that, after leaving the hypoxic (i.e., lacking oxygen) environment deep in the tumor, enter the bloodstream and spread. Scientists have identified 16 genes that breast cancer cells use to survive in the bloodstream. Each of these genes can become a therapeutic target to stop cancer recurrence, one of which has already been in clinical trials. The research was reported on in Nature Communications.
  • Researchers from Northwestern University have found an unexpected connection between COVID-19 infection and cancer regression. They discovered that the RNA from the SARS-CoV-2 virus that causes COVID-19 triggers the development of a unique type of immunity that can fight cancer. The discovery may lay a foundation for novel cancer treatments. The study was published in The Journal of Clinical Investigation.
  • Researchers from MD Anderson found significant survival benefits in patients who quit smoking after cancer diagnosis. “The best outcomes were observed in patients who started tobacco treatment within six months of a cancer diagnosis and were abstinent from smoking three months later.” The study was published in JAMA Oncology.